Abstract
Immunoreactive prostate-specific antigen (PSA) has been detected in the sera of female and male renal cell carcinoma (RCC) patients in several studies (1)(2)(3). These measurements were attributed to the tumor because PSA reverted to undetectable concentrations after nephrectomy. However, attempts to definitively ascribe this increase to PSA were not successful either by immunohistochemistry with PSA monoclonal antibodies (1)(2) or by amplification of PSA by reverse transcription-PCR (RT-PCR) (3), suggesting cross-reaction with a PSA-like protein. Prostaglandin D synthase (PGDS) in amniotic fluid has been found to cross-react with a PSA polyclonal antibody, but not with PSA monoclonal antibodies (4). PGDS is present …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
